Brilliant Violet 421™ anti-mouse CD8a | BioLegend 100753 product information

product summary

company name :

BioLegend

other brands :

Babco, Signet, Sternberger Monoclonals, Senetek, Covance

product type :

antibody

product name :

Brilliant Violet 421™ anti-mouse CD8a

catalog :

100753

quantity :

50 μg

price :

230 USD

clonality :

monoclonal

host :

rat

conjugate :

BV421

clone name :

53-6.7

reactivity :

mouse

application :

immunohistochemistry, flow cytometry

more info or order :

BioLegend product webpage

citations: 29

Published Application/Species/Sample/Dilution	Reference
flow cytometry; mouse; loading ...; fig 1c	Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher
flow cytometry; mouse; fig 2a	Hu Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7:279ra41 pubmed publisher
	LaFleur M, Nguyen T, Coxe M, Yates K, Trombley J, Weiss S, et al. A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. Nat Commun. 2019;10:1668 pubmed publisher
	Zwick M, Ulas T, Cho Y, Ried C, Grosse L, Simon C, et al. Expression of the Phosphatase Ppef2 Controls Survival and Function of CD8+ Dendritic Cells. Front Immunol. 2019;10:222 pubmed publisher
	Groza D, Gehrig S, Kudela P, Holcmann M, Pirker C, Dinhof C, et al. Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. Oncoimmunology. 2018;7:e1424676 pubmed publisher
	Klepsch V, Hermann Kleiter N, Do Dinh P, Jakic B, Offermann A, Efremova M, et al. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nat Commun. 2018;9:1538 pubmed publisher
	Pavelko K, Bell M, Harrington S, Dong H. B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System. Front Immunol. 2017;8:1532 pubmed publisher
	Snell L, Osokine I, Yamada D, de la Fuente J, Elsaesser H, Brooks D. Overcoming CD4 Th1 Cell Fate Restrictions to Sustain Antiviral CD8Â T Cells and Control Persistent Virus Infection. Cell Rep. 2016;16:3286-3296 pubmed publisher
	Ding Z, Dahlin J, Xu H, Heyman B. IgE-mediated enhancement of CD4(+) T cell responses requires antigen presentation by CD8Î±(-) conventional dendritic cells. Sci Rep. 2016;6:28290 pubmed publisher
	Cui L, Osada K, Imaizumi A, Kataoka K, Nakano K. Feasibility of a subcutaneously administered block/homo-mixed polyplex micelle as a carrier for DNA vaccination in a mouse tumor model. J Control Release. 2015;206:220-31 pubmed publisher
	Ballet R, Emre Y, Jemelin S, Charmoy M, Tacchini Cottier F, Imhof B. Blocking junctional adhesion molecule C enhances dendritic cell migration and boosts the immune responses against Leishmania major. PLoS Pathog. 2014;10:e1004550 pubmed publisher
	Chen Z, Ozbun L, Chong N, Wallecha A, Berzofsky J, Khleif S. Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3- and CD8+ T cells. Cancer Immunol Res. 2014;2:911-22 pubmed publisher
	del Rio M, Cote Sierra J, Rodriguez Barbosa J. Flt3L-mobilized dendritic cells bearing H2-Kbm1 apoptotic cells do not induce cross-tolerance to CD8+ T cells across a class I MHC mismatched barrier. Transpl Int. 2011;24:501-13 pubmed publisher
	Apte S, Groves P, Olver S, Baz A, Doolan D, Kelso A, et al. IFN-gamma inhibits IL-4-induced type 2 cytokine expression by CD8 T cells in vivo and modulates the anti-tumor response. J Immunol. 2010;185:998-1004 pubmed publisher
	Bankoti J, Burnett A, Navarro S, Miller A, Rase B, Shepherd D. Effects of TCDD on the fate of naive dendritic cells. Toxicol Sci. 2010;115:422-34 pubmed publisher
	Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman A, et al. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood. 2010;115:1175-84 pubmed publisher
	Todd D, McHeyzer Williams L, Kowal C, Lee A, Volpe B, Diamond B, et al. XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J Exp Med. 2009;206:2151-9 pubmed publisher
	Riedl P, Wieland A, Lamberth K, Buus S, Lemonnier F, Reifenberg K, et al. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential. J Immunol. 2009;183:370-80 pubmed publisher
	Lee C, Chiang Y, Chang S, Chong C, Cheng B, Roffler S. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses. Clin Cancer Res. 2009;15:2756-66 pubmed publisher
	Britschgi M, Link A, Lissandrin T, Luther S. Dynamic modulation of CCR7 expression and function on naive T lymphocytes in vivo. J Immunol. 2008;181:7681-8 pubmed
	Kingeter L, Schaefer B. Loss of protein kinase C theta, Bcl10, or Malt1 selectively impairs proliferation and NF-kappa B activation in the CD4+ T cell subset. J Immunol. 2008;181:6244-54 pubmed
	Geiben Lynn R, Greenland J, Frimpong Boateng K, Van Rooijen N, Hovav A, Letvin N. CD4+ T lymphocytes mediate in vivo clearance of plasmid DNA vaccine antigen expression and potentiate CD8+ T-cell immune responses. Blood. 2008;112:4585-90 pubmed publisher
	Jordan J, Woods M, Olano J, Walker D. The absence of Toll-like receptor 4 signaling in C3H/HeJ mice predisposes them to overwhelming rickettsial infection and decreased protective Th1 responses. Infect Immun. 2008;76:3717-24 pubmed publisher
	Guo Y, Maillard I, Chakraborti S, Rothenberg E, Speck N. Core binding factors are necessary for natural killer cell development and cooperate with Notch signaling during T-cell specification. Blood. 2008;112:480-92 pubmed publisher
	Andrews D, Andoniou C, Fleming P, Smyth M, Degli Esposti M. The early kinetics of cytomegalovirus-specific CD8+ T-cell responses are not affected by antigen load or the absence of perforin or gamma interferon. J Virol. 2008;82:4931-7 pubmed publisher
	Kenna T, Thomas R, Steptoe R. Steady-state dendritic cells expressing cognate antigen terminate memory CD8+ T-cell responses. Blood. 2008;111:2091-100 pubmed
	Rasmussen J, Cello J, Gil H, Forestal C, Furie M, Thanassi D, et al. Mac-1+ cells are the predominant subset in the early hepatic lesions of mice infected with Francisella tularensis. Infect Immun. 2006;74:6590-8 pubmed
	Kao C, Daniels M, Jameson S. Loss of CD8 and TCR binding to Class I MHC ligands following T cell activation. Int Immunol. 2005;17:1607-17 pubmed
	Ko S, Ko H, Chang W, Park S, Kweon M, Kang C. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol. 2005;175:3309-17 pubmed

product information

Antigen :

CD8a

Apps. Abbrev. :

Flow Cytometry, IHC

Cat # :

100753

Clone :

53-6.7

Item :

Brilliant Violet 421™ anti-mouse CD8a

Isotype :

Rat IgG2a, κ

Other Names :

T8, Lyt2, Ly-2

Size :

50 μg

Price (USD) :

230 USD

Reactivity :

Mouse

Clonality :

Monoclonal

Host :

Rat

Conjugate/Tag/Label :

BV421

Immunogen :

Mouse thymus or spleen

Application Notes :

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes 3 . The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a + cells. Additional reported applications (for the relevant formats) include: immunoprecipitation 1,3 , in vivo and in vitro cell depletion 2,10,15 , inhibition of CD8 T cell proliferation 3 , blocking of cytotoxicity 3,4 , and immunohistochemical staining 5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin 0.01 EU/µg, Azide-Free, 0.2 μm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

more info or order :

BioLegend product webpage